The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1722
February 17, 2025
View Complete Issue         Table of Contents 2019 
Vadadustat (Vafseo) for Anemia of Chronic Kidney Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vadadustat (Vafseo) for Anemia of Chronic Kidney Disease
February 17, 2025 (Issue: 1722)
The FDA has approved the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) vadadustat (Vafseo – Akebia) for oral treatment of anemia due to chronic kidney disease (CKD) in adults who have been on dialysis for at least 3 months....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Vadadustat (Vafseo) for Anemia of Chronic Kidney Disease
Article code: 1722b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.